Neurocrine Biosciences Inc.
Neurocrine Biosciences (NBIX) is a US-based biopharmaceutical company focused on neurological and endocrine disorders. Its commercial franchise centres on a marketed therapy for tardive dyskinesia alongside other marketed products and collaborative agreements that help broaden revenue streams; a pipeline of clinical-stage programmes aims to extend future growth. With a market capitalisation around $14.15 billion, its financial performance is driven by product sales, licencing deals and R&D progress. Investors should note regulatory review, patent lifecycles and competitive alternatives are constant risks, and share price volatility often accompanies trial readouts and approval decisions. This summary is for educational purposes and not personal investment advice. Before investing, consider whether NBIX fits your goals and risk tolerance, review the company’s filings and consult a qualified adviser if you need personalised guidance. Values can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Neurocrine Biosciences stock, expecting it to rise towards $162.09.
Financial Health
Neurocrine Biosciences is performing strongly, with high profits, cash flow, and revenue growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring NBIX
Pharma's Renewed Focus On Mental Health
AbbVie's potential $1 billion acquisition of Gilgamesh Pharmaceuticals signals a major strategic investment in the mental health sector. This move is expected to increase M&A interest and valuations for other biotech firms developing innovative psychiatric therapies.
Published: July 31, 2025
Explore BasketSafer Alzheimer's Treatments
This carefully selected group of stocks represents companies at the forefront of developing safer, more effective Alzheimer's treatments. The FDA's recent approval of improved dosing for breakthrough therapies has created significant new opportunities in this rapidly evolving field.
Published: July 11, 2025
Explore BasketBrain-Computer Interface
This collection features pioneering companies creating revolutionary pathways between the human brain and machines. These carefully selected stocks represent the cutting edge of neural technology, with potential to transform healthcare and computing through innovative brain signal interpretation.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercial Momentum
Product sales and licencing deals have driven recent revenues; commercial uptake matters for near-term performance, though results can vary and face competitive pressures.
Pipeline Catalysts
Clinical trial readouts and regulatory milestones can be major share-price drivers; these events also carry binary risk if outcomes disappoint.
Partnerships & Reach
Collaborations and geographic expansion can amplify commercial potential, but licencing terms and market competition affect long-term returns.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ARCELLX, INC.
Develops T-cell therapies for the treatment of cancer.
AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
